Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials (Q34372086)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

0 references

Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

0 references

0 references

0 references

3

object named as

Cyrille Hulin

0 references

8

object named as

Xavier Leleu

0 references

object named as

Ileana Baldi

19

0 references

Giovannino Ciccone

object named as

Giovannino Ciccone

21

0 references

Pieter Sonneveld

26

object named as

Pieter Sonneveld

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Antonio Palumbo

1

object named as

Antonio Palumbo

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

5

object named as

Sonja Zweegman

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Henk M. Lokhorst

23

object named as

Henk Lokhorst

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Bronno van der Holt

18

object named as

Bronno van der Holt

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

4

object named as

Meral Beksac

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

author name string

Anders Waage

2

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Francesca Gay

6

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Peter Gimsing

7

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Pierre Wijermans

9

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Gülsan Sucak

10

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Sara Pezzatti

11

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Gunnar Juliusson

12

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Brigitte Pégourié

13

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Martijn Schaafsma

14

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Monica Galli

15

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Ingemar Turesson

16

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Brigitte Kolb

17

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Jürgen Rolke

20

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Marc Wetterwald

22

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Mario Boccadoro

24

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Philippe Rodon

25

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

publication date

8 August 2012

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

98

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

87-94

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Need to realign patient-oriented and commercial and academic research.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533664

6 July 2018

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533664

6 July 2018

Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533664

6 July 2018

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533664

6 July 2018

Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533664

6 July 2018

Thalidomide for treatment of multiple myeloma: 10 years later

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533664

6 July 2018

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533664

6 July 2018

Analysing multicentre competing risks data with a mixed proportional hazards model for the subdistribution

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533664

6 July 2018

Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533664

6 July 2018

International staging system for multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533664

6 July 2018

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533664

6 July 2018

Aging and pharmacology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533664

6 July 2018

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533664

6 July 2018

Altered pharmacokinetics in the elderly.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533664

6 July 2018

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533664

6 July 2018

Multiple Myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533664

27 October 2018

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533664

27 October 2018

Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533664

27 October 2018

Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533664

27 October 2018

Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533664

27 October 2018

Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533664

27 October 2018

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533664

27 October 2018

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533664

27 October 2018

Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/22875621

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions

1 reference

https://pubmed.ncbi.nlm.nih.gov/22875621

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/22875621

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3324/HAEMATOL.2012.067058

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34372086&oldid=2010746772"